Cargando…

Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk

INTRODUCTION: Results conflict on the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk, despite wide-ranging investigations. This meta-analysis examines whether the XRCC2 rs3218536 polymorphism is associated with ovarian cancer risk. MATERIAL AND METHODS: Eligible case-co...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Cunzhong, Liu, Xiaoyan, Li, Rongrong, Yan, Shi, Kong, Beihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212224/
https://www.ncbi.nlm.nih.gov/pubmed/32399118
http://dx.doi.org/10.5114/aoms.2020.94657
_version_ 1783531579842232320
author Yuan, Cunzhong
Liu, Xiaoyan
Li, Rongrong
Yan, Shi
Kong, Beihua
author_facet Yuan, Cunzhong
Liu, Xiaoyan
Li, Rongrong
Yan, Shi
Kong, Beihua
author_sort Yuan, Cunzhong
collection PubMed
description INTRODUCTION: Results conflict on the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk, despite wide-ranging investigations. This meta-analysis examines whether the XRCC2 rs3218536 polymorphism is associated with ovarian cancer risk. MATERIAL AND METHODS: Eligible case-control studies were searched in PubMed. We therefore performed a meta-analysis of 5,802 ovarian cancer cases and 9,390 controls from 7 articles published. The strength of association between XRCC2 rs3218536 polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). RESULTS: No statistically significant associations between XRCC2 rs3218536 polymorphism and ovarian cancer risk were found in any genetic models. However, a significant relationship with ovarian cancer risk was discovered when the high quality studies were pooled in the meta-analysis (AA vs. GG: OR = 0.59, 95% CI: 0.37–0.94, p = 0.03; GA vs. GG: OR = 0.87, 95% CI: 0.78–0.96, p = 0.009; GA + AA vs. GG: OR = 0.85, 95% CI: 0.77–0.94, p = 0.003; AA vs. GG + GA: OR = 0.60, 95% CI: 0.38–0.95, p = 0.03). CONCLUSIONS: This meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with ovarian cancer risk overall for high quality studies. Non-Caucasian groups and high quality studies should be further studied.
format Online
Article
Text
id pubmed-7212224
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-72122242020-05-12 Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk Yuan, Cunzhong Liu, Xiaoyan Li, Rongrong Yan, Shi Kong, Beihua Arch Med Sci Basic Research INTRODUCTION: Results conflict on the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk, despite wide-ranging investigations. This meta-analysis examines whether the XRCC2 rs3218536 polymorphism is associated with ovarian cancer risk. MATERIAL AND METHODS: Eligible case-control studies were searched in PubMed. We therefore performed a meta-analysis of 5,802 ovarian cancer cases and 9,390 controls from 7 articles published. The strength of association between XRCC2 rs3218536 polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). RESULTS: No statistically significant associations between XRCC2 rs3218536 polymorphism and ovarian cancer risk were found in any genetic models. However, a significant relationship with ovarian cancer risk was discovered when the high quality studies were pooled in the meta-analysis (AA vs. GG: OR = 0.59, 95% CI: 0.37–0.94, p = 0.03; GA vs. GG: OR = 0.87, 95% CI: 0.78–0.96, p = 0.009; GA + AA vs. GG: OR = 0.85, 95% CI: 0.77–0.94, p = 0.003; AA vs. GG + GA: OR = 0.60, 95% CI: 0.38–0.95, p = 0.03). CONCLUSIONS: This meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with ovarian cancer risk overall for high quality studies. Non-Caucasian groups and high quality studies should be further studied. Termedia Publishing House 2020-04-25 /pmc/articles/PMC7212224/ /pubmed/32399118 http://dx.doi.org/10.5114/aoms.2020.94657 Text en Copyright: © 2019 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Basic Research
Yuan, Cunzhong
Liu, Xiaoyan
Li, Rongrong
Yan, Shi
Kong, Beihua
Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk
title Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk
title_full Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk
title_fullStr Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk
title_full_unstemmed Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk
title_short Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk
title_sort analysis of the association between the xrcc2 rs3218536 polymorphism and ovarian cancer risk
topic Basic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212224/
https://www.ncbi.nlm.nih.gov/pubmed/32399118
http://dx.doi.org/10.5114/aoms.2020.94657
work_keys_str_mv AT yuancunzhong analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk
AT liuxiaoyan analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk
AT lirongrong analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk
AT yanshi analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk
AT kongbeihua analysisoftheassociationbetweenthexrcc2rs3218536polymorphismandovariancancerrisk